Mark D. Kaufmann, MD, FAAD
BIOGRAPHY
Mark Kaufmann, MD, is a Clinical Professor in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York City and a former President of the American Academy of Dermatology (AAD). Dr. Kaufmann was in solo private practice for 23 years until he joined The Dermatology Group in November 2017. In September 2020, he joined Advanced Dermatology and Cosmetic Surgery as their Chief Medical Officer. Dr. Kaufmann has served on the AAD Board of Directors as well as serving as Chair for many AAD committees. In addition, Dr. Kaufmann currently serves on the Board of Directors of the American Society for Dermatologic Surgery, the Florida Academy of Dermatology, and is an advisor to the AAD RUC team (Relative Value Scale Update Committee) - a position he has held for over a decade. Dr. Kaufmann received his medical degree from New York University School of Medicine, completing residency training in dermatology at the Albert Einstein College of Medicine in the Bronx, New York and is board certified in dermatology. Dr. Kaufmann’s contributions to the American Academy of Dermatology have been recognized by his receiving a Presidential Citation in 2013, 2014, 2015, 2017, 2020, 2022, and 2024. With many articles published on the topic of health information technology, Dr. Kaufmann is a frequent national lecturer, including the AAD Annual Meeting, other national and regional societies, and grand rounds.
SESSIONS
DISCLOSURES
Almirall – Consultant (1099 relationship)(Fees); Apogee Therapeutics – Consultant (1099 relationship)(Fees); Avita Medical – Consultant (1099 relationship)(Fees); Biofrontera – Consultant (1099 relationship)(Fees); Dermsquared – Other(Fees); DermTech Inc. – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Incyte – Consultant (1099 relationship)(Fees); Modernizing Medicine – Consultant(Stock); MoleSafe, Inc. – Other(Stock); Novan – Consultant (1099 relationship)(Fees); Novartis – Consultant (1099 relationship)(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pelthos Therapeutics – Consultant (1099 relationship)(Fees); Rise Healthcare Tech, Inc. – Advisory Board(Stock Options); Rivera Consulting – Consultant (1099 relationship)(Fees); ROM Technologies Inc. – Consultant (1099 relationship)(Stock); Sanofi/Regeneron – Consultant (1099 relationship)(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB Pharma – Consultant (1099 relationship)(Fees); Verrica Pharmaceuticals Inc – Consultant (1099 relationship)(Fees);